Sinopharm Tech Holdings Limited (8156) Ratios

0 Followers

Sinopharm Tech Holdings Limited Ratios

HK:8156's free cash flow for Q3 2024 was HK$0.18. For the 2024 fiscal year, HK:8156's free cash flow was decreased by HK$ and operating cash flow was HK$-0.14. See a summary of the company’s cash flow.

Ratios	TTM	Jun 24	Jun 23	Jun 22	Jun 21
Liquidity Ratios
Current Ratio	―	0.72	0.15	0.13	0.19
Quick Ratio	―	0.52	0.14	0.12	0.19
Cash Ratio	―	0.10	0.01	<0.01	0.01
Solvency Ratio	―	<0.01	-0.07	-0.04	-0.34
Operating Cash Flow Ratio	―	-0.11	-0.04	0.02	-0.15
Short-Term Operating Cash Flow Coverage	―	-0.27	-0.13	0.09	-0.82
Net Current Asset Value	HK$ ―	HK$ -39.30M	HK$ -212.02M	HK$ -186.19M	HK$ -202.21M
Leverage Ratios
Debt-to-Assets Ratio	―	0.90	1.65	1.58	0.60
Debt-to-Equity Ratio	―	-1.27	-0.37	-0.31	-0.28
Debt-to-Capital Ratio	―	4.74	-0.58	-0.44	-0.38
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	0.00	0.00
Financial Leverage Ratio	―	-1.40	-0.22	-0.19	-0.46
Debt Service Coverage Ratio	―	0.18	0.05	<0.01	-1.22
Interest Coverage Ratio	―	-1.22	-0.38	-10.59	-3.54
Debt to Market Cap	―	0.31	3.56	0.83	0.08
Interest Debt Per Share	―	0.11	0.53	0.34	0.35
Net Debt to EBITDA	―	6.51	14.18	-50.46	-0.57
Profitability Margins
Gross Profit Margin	―	22.06%	12.16%	12.77%	12.44%
EBIT Margin	―	7.80%	8.72%	-7.05%	-189.70%
EBITDA Margin	―	9.97%	12.06%	-2.37%	-183.41%
Operating Profit Margin	―	-11.64%	-22.20%	-211.91%	-141.56%
Pretax Profit Margin	―	-1.76%	-49.26%	-25.33%	-229.74%
Net Profit Margin	―	-1.42%	-47.72%	-24.83%	-214.71%
Continuous Operations Profit Margin	―	-2.24%	-49.46%	-22.27%	-228.79%
Net Income Per EBT	―	80.35%	96.88%	98.03%	93.46%
EBT Per EBIT	―	15.14%	221.89%	11.95%	162.29%
Return on Assets (ROA)	―	-1.68%	-44.28%	-31.76%	-114.45%
Return on Equity (ROE)	―	2.35%	9.87%	6.16%	52.76%
Return on Capital Employed (ROCE)	―	42.84%	4.47%	50.50%	33.46%
Return on Invested Capital (ROIC)	―	-71.00%	6.92%	62.99%	45.33%
Return on Tangible Assets	―	-1.68%	-44.28%	-31.76%	-114.45%
Earnings Yield	―	-1.01%	-97.48%	-16.62%	-16.31%
Efficiency Ratios
Receivables Turnover	―	2.32	1.45	1.87	0.97
Payables Turnover	―	2.08	1.12	1.07	0.64
Inventory Turnover	―	3.54	10.25	43.71	51.40
Fixed Asset Turnover	―	23.53	10.63	36.83	7.90
Asset Turnover	―	1.18	0.93	1.28	0.53
Working Capital Turnover Ratio	―	-0.53	-0.21	-0.22	-0.19
Cash Conversion Cycle	―	85.21	-38.99	-137.49	-183.59
Days of Sales Outstanding	―	157.56	252.51	195.35	377.74
Days of Inventory Outstanding	―	103.07	35.61	8.35	7.10
Days of Payables Outstanding	―	175.43	327.11	341.20	568.42
Operating Cycle	―	260.63	288.12	203.70	384.84
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.02	-0.05	0.03	-0.20
Free Cash Flow Per Share	―	-0.02	-0.07	0.03	-0.21
CapEx Per Share	―	0.00	0.02	0.00	<0.01
Free Cash Flow to Operating Cash Flow	―	1.00	1.36	1.00	1.00
Dividend Paid and CapEx Coverage Ratio	―	0.00	-2.78	0.00	-303.83
Capital Expenditure Coverage Ratio	―	0.00	-2.78	0.00	-303.83
Operating Cash Flow Coverage Ratio	―	-0.15	-0.13	0.09	-0.80
Operating Cash Flow to Sales Ratio	―	-0.12	-0.22	0.11	-0.90
Free Cash Flow Yield	―	-8.38%	-62.26%	7.39%	-6.84%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-99.18	-1.03	-6.02	-6.13
Price-to-Sales (P/S) Ratio	―	1.40	0.49	1.49	13.17
Price-to-Book (P/B) Ratio	―	-2.33	-0.10	-0.37	-3.24
Price-to-Free Cash Flow (P/FCF) Ratio	―	-11.93	-1.61	13.52	-14.63
Price-to-Operating Cash Flow Ratio	―	-11.93	-2.18	13.52	-14.68
Price-to-Earnings Growth (PEG) Ratio	―	1.01	-0.01	0.07	0.29
Price-to-Fair Value	―	-2.33	-0.10	-0.37	-3.24
Enterprise Value Multiple	―	20.59	18.24	-113.52	-7.75
Enterprise Value	―	125.77M	90.82M	115.23M	582.58M
EV to EBITDA	―	20.59	18.24	-113.52	-7.75
EV to Sales	―	2.05	2.20	2.69	14.21
EV to Free Cash Flow	―	-17.45	-7.22	24.35	-15.79
EV to Operating Cash Flow	―	-17.45	-9.82	24.35	-15.85
Tangible Book Value Per Share	―	-0.08	-1.12	-0.98	-0.96
Shareholders’ Equity Per Share	―	-0.08	-1.09	-0.94	-0.93
Tax and Other Ratios
Effective Tax Rate	―	-0.27	>-0.01	0.12	<0.01
Revenue Per Share	―	0.13	0.22	0.23	0.23
Net Income Per Share	―	>-0.01	-0.11	-0.06	-0.49
Tax Burden	―	0.80	0.97	0.98	0.93
Interest Burden	―	-0.23	-5.65	3.59	1.21
Research & Development to Revenue	―	0.00	0.00	0.00	0.00
SG&A to Revenue	―	0.34	0.33	0.46	1.01
Stock-Based Compensation to Revenue	―	0.00	0.02	0.06	0.11
Income Quality	―	8.31	0.46	-0.41	0.39

Currency in HKD